1. Home
  2. DH vs LCTX Comparison

DH vs LCTX Comparison

Compare DH & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DH
  • LCTX
  • Stock Information
  • Founded
  • DH 2011
  • LCTX 1990
  • Country
  • DH United States
  • LCTX United States
  • Employees
  • DH N/A
  • LCTX N/A
  • Industry
  • DH Computer Software: Prepackaged Software
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • DH Technology
  • LCTX Health Care
  • Exchange
  • DH Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • DH 298.7M
  • LCTX 274.0M
  • IPO Year
  • DH 2021
  • LCTX N/A
  • Fundamental
  • Price
  • DH $2.68
  • LCTX $1.84
  • Analyst Decision
  • DH Hold
  • LCTX Strong Buy
  • Analyst Count
  • DH 5
  • LCTX 4
  • Target Price
  • DH $4.35
  • LCTX $4.25
  • AVG Volume (30 Days)
  • DH 269.1K
  • LCTX 1.8M
  • Earning Date
  • DH 11-06-2025
  • LCTX 11-06-2025
  • Dividend Yield
  • DH N/A
  • LCTX N/A
  • EPS Growth
  • DH N/A
  • LCTX N/A
  • EPS
  • DH N/A
  • LCTX N/A
  • Revenue
  • DH $244,926,000.00
  • LCTX $10,914,000.00
  • Revenue This Year
  • DH N/A
  • LCTX N/A
  • Revenue Next Year
  • DH $0.68
  • LCTX $176.00
  • P/E Ratio
  • DH N/A
  • LCTX N/A
  • Revenue Growth
  • DH N/A
  • LCTX 76.43
  • 52 Week Low
  • DH $2.15
  • LCTX $0.37
  • 52 Week High
  • DH $5.68
  • LCTX $1.87
  • Technical
  • Relative Strength Index (RSI)
  • DH 27.50
  • LCTX 65.48
  • Support Level
  • DH $2.87
  • LCTX $1.66
  • Resistance Level
  • DH $3.02
  • LCTX $1.79
  • Average True Range (ATR)
  • DH 0.14
  • LCTX 0.11
  • MACD
  • DH 0.00
  • LCTX -0.01
  • Stochastic Oscillator
  • DH 0.00
  • LCTX 91.18

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: